Summary Reduced pulmonary function is an important predictor of cardiovascular morbidity and mortality. The mechanisms underlying this association are unknown but may involve systemic inflammation. We assessed the cross-sectional and longitudinal relationships between C-reactive protein (CRP) levels and forced expiratory volume in 1 s (FEV 1 ) and its decline in the general population, over a period of 8.5 years.
Reduced pulmonary function, as assessed by peak expiratory flow, forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC), is associated with an increase in the occurrence of vascular alterations and cardiovascular morbidity and mortality, in both smokers and non-smokers. [1] [2] [3] [4] [5] [6] [7] Systemic inflammation may play a key role in the development of cardiovascular risk [8] [9] [10] and reduced pulmonary function. [11] [12] [13] [14] There are various markers of systemic inflammation. C-reactive protein (CRP), an acute-phase reactant produced primarily in the liver in response to interleukin-6, is the best studied, and its concentration has consistently been shown to be strongly related to future cardiovascular risk in healthy subjects and in patients with peripheral and stable coronary artery diseases. [15] [16] [17] Systemic inflammation may also be involved in lung function decline, as suggested by the results of the few available cross-sectional populationbased studies. FVC has been reported to be inversely associated with levels of inflammationsensitive serum proteins. 18 A lower FEV 1 and an increased risk of chronic obstructive pulmonary disease (COPD) have also been shown to be associated with high serum fibrinogen concentration. 12 High serum CRP concentrations have been reported in patients with COPD, which is a major cause of reduced FEV 1 . 19 However, the relationships between serum CRP concentration and lung function have not been studied in detail. A few cross-sectional studies, including one carried out by our group, have investigated the association between serum CRP concentration and pulmonary function in the general population. 20, 21 In these studies, FEV 1 was inversely associated with CRP concentration.
Cross-sectional studies cannot be used to determine direction-and time-dependent relationships. No longitudinal study has investigated the relationship between changes in CRP concentration and pulmonary function decline over time.
In this 8 1 2 year longitudinal study, conducted in 531 subjects aged between 20 and 44 years at baseline, recruited at two French centers participating in the European Community Respiratory Health Survey (ECRHS), we assessed the associations between changes in CRP concentration and annual FEV 1 decline.
Methods
The ECRHS is an international, longitudinal, multicenter epidemiological survey of asthma (prevalence, determinants, and management) in Europe. Full details of the original sampling protocol have been published elsewhere. 22, 23 In the baseline study in 1991, 660 subjects (Paris) and 534 subjects (Grenoble) aged 20-44 years were randomly selected from the electoral rolls of Paris (18th Arrondissement) and Grenoble. These subjects were interviewed and examined. Subjects who had suffered from respiratory infection in the 3 weeks immediately preceding the examination were asked to postpone their examination if possible, as this was a criterion for exclusion. Each subject completed a standardized questionnaire and underwent standardized lung function and blood tests.
Between 1999 and 2001 (8.5 years of follow-up on average), all subjects from the baseline study were contacted again and asked to undergo examination again for the follow-up study. In the two centers, 684 subjects agreed to participate in the follow-up study. Participants and non-participants did not differ in sex distribution, body mass index (BMI) 
Data collection
At baseline and follow-up, trained interviewers used a standardized questionnaire to collect sociodemographic information and data concerning respiratory symptoms during the preceding 12 months, smoking history, allergic symptoms, family history, home and work environment, and use of health-care services and medication. Subjects were classified as never having smoked, past smokers (those who had stopped smoking at least 1 year before the examination), heavy smokers (if their current tobacco consumption was at least 20 g per day) and light smokers (for those consuming up to 20 g of tobacco per day). Baseline ''asthma'' was defined as a positive response to any of the following questions: ''Have you had an asthma attack in the last 12 months?'' and/or ''Are you currently taking any medication for asthma?''. BMI was calculated as weight in kilograms divided by the square of height in meters.
Lung function measurements
FEV 1 was measured with a water-sealed bell spirometer (Biomedin srl, Padova, Italy). The highest of five technically acceptable FEV 1 readings was used for analysis. FEV 1 was expressed as a percentage of predicted values (FEV 1 % predicted) calculated based on age and height for men and women, using ECSC reference equations. 24 
Biological measurements
Blood samples were collected at baseline and during follow-up studies and frozen at À80 1C. We determined the levels of IgE specific for house dust mite, cat, timothy grass and Cladosporium in serum samples. Tests for specific IgE were considered positive if values 40.35 kU/l were obtained.
''Atopy'' was defined as at least one positive specific IgE test. Total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) concentrations were determined by enzymatic methods, using an automatic analyzer. Serum CRP concentrations were determined from frozen blood samples stored in the Biochemistry Department of Bichat Hospital, Paris, by means of an ultra-sensitive competitive immunoassay on a BN II analyzer (Dade Behring, Marburg, Germany). The intra-and interassay coefficients of variation were both o10%.
Statistical analysis
Statistical analysis was carried out with SAS version 8.2 (SAS Institute Inc., Cary, NC, USA). Data are expressed as percentages for discrete variables and as means7standard deviations for continuous variables. We considered P-values o0.05 to be significant.
We carried out a cross-sectional analysis on data collected in 1991 (baseline). CRP concentrations were not normally distributed and analyzes were therefore performed with log-transformed values divided into tertiles (the tertile cut-off points for CRP concentration were 0.5 and 1.3 mg/l). We investigated the cross-sectional association between CRP and FEV 1 % predicted by analysis of variance for univariate analyzes and analysis of covariance for multivariate analyzes (with FEV 1 % predicted as the dependent variable). Cross-sectional multivariate analyzes were adjusted for sex, center, age, BMI, total cholesterol concentration, smoking habits (never, past, light, and heavy smokers), atopy and asthma. For the longitudinal analysis, annual FEV 1 decline (ml/year) was calculated as the difference between follow-up and baseline observed FEV 1 values, divided by the number of months between the two surveys, multiplied by 12. The change in serum CRP concentration during follow-up was calculated by subtracting CRP concentration at follow-up from baseline CRP concentration. Subjects were divided into tertiles according to mean change in CRP concentration (tertile cut-off points for change in CRP concentration were À0.1 and 0.5 mg/l and mean7SD for each tertile of CRP change were À1.872.8, 0.170.1, and 3.074.4 mg/l, respectively). In the first tertile-''decrease''-CRP concentrations decreased over time. In the second tertile-''no change''-CRP concentrations remained stable and in the third tertile-''increase''-CRP concentrations increased over time.
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Categories of change in smoking habits were derived, which included never smokers, sustained quitters, smokers (at each survey), quitters (stopped between surveys), and restarters.
We used analysis of variance and analysis of covariance to describe the differences in mean annual FEV 1 decline between the tertiles of both baseline CRP and change in CRP concentration, with and without adjustment for center, sex, and baseline age, BMI, total cholesterol concentration, smoking habits, atopy, asthma and FEV 1 . In addition, changes in these confounding factors during follow-up were included in the multivariable model to assess its potential effects on this relationship.
We excluded 153 of the 684 subjects from the analysis, for the following reasons: missing data for serum CRP concentration (n ¼ 144, due to the refusal of the subject to provide blood samples or technical and organizational difficulties) and/or missing pulmonary function tests (n ¼ 14). This left 531 subjects for whom complete data were available for cross-sectional and longitudinal analysis. The 531 subjects with complete data were older at baseline (37.077.0 vs. 35.677.1 years, P ¼ 0:03) than the excluded subjects and the percentage of men was higher (50.0% vs. 39.0%, P ¼ 0:01). The mean duration of follow-up was 8.570.8 years.
Men had a higher mean baseline FEV 1 % predicted than women but serum CRP concentrations were similar in men and women.
Results
Mean baseline age (7SD) for the 531 subjects (50% men) included in this study was 37.077.0 years. About 42% of this population was non-smoker . As expected, mean BMI and mean total cholesterol concentrations were significantly higher in men than in women. Women had higher serum concentrations of HDL than men. Heavy smokers were more frequent in men than in women (results not shown). Men had a higher mean baseline FEV 1 % predicted than women (107714 vs. 104713, Po0:01) but serum CRP concentrations were similar in men and women (1.5772.5 vs. 1.6072.5, P ¼ 0:86). Baseline characteristics were compared by tertiles of baseline CRP. CRP was positively associated with BMI (Po0:001), smoking status (Po0:01), total cholesterol (Po0:001) and asthma (P ¼ 0:05) (results available from authors).
Cross-sectional analysis
At baseline, FEV 1 % predicted was negatively associated with serum CRP concentration. Crude mean values of FEV 1 % predicted according to CRP tertiles were 106714%, 107713%, and 102714% for lower, middle and upper tertiles, respectively (P ¼ 0:002).
Similar results were obtained in multivariate analyzes: the participants with the highest serum CRP concentrations had the lowest values of FEV 1 % predicted (Table 2) . This pattern applied to the various subgroups. The associations between CRP concentration and FEV 1 % predicted were weaker (and not significant) in those who had never smoked. However, the interaction between CRP concentration and smoking habits was not statistically significant (P ¼ 0:5).
Longitudinal study
A significant correlation was observed between baseline CRP and CRP at follow-up (correlation coefficient ¼ 0.50, Po0:001) and also between baseline FEV 1 %predicted and FEV 1 %predicted at follow-up (correlation coefficient ¼ 0.83, Po0:001).
Mean annual decline in FEV 1 (7SD) was 30732 ml/year (Po0:001). CRP concentration increased over time and the mean change in CRP concentration over the eight and a half years of follow-up was 0.573.6 mg/l (P ¼ 0:004). Baseline BMI, smoking and asthma were positively associated with change in CRP concentration over time. Baseline FEV 1 was not associated with CRP change (Table 3) . Annual FEV 1 decline was positively associated with being female, age, smoking, and BMI at baseline (results available from the authors). Table 4 shows the relationship between baseline CRP and FEV 1 decline. Annual FEV 1 decline tended to increase from the lower to the upper tertile for baseline CRP concentration but this relationship did not reach statistical significance. After adjustment for covariates including, center, sex, baseline age, smoking habits, BMI, asthma, atopy, FEV 1 and change in CRP concentration, the association between baseline CRP and annual FEV 1 decline concentration was borderline significant (P ¼ 0:09), but a significant difference in mean FEV 1 decline was seen between the highest and lowest tertiles for baseline CRP (P ¼ 0:03).
Changes in CRP concentration during follow-up were negatively correlated with FEV 1 decline (correlation coefficient ¼ À0.15, Po0:001- Fig. 1 ). Mean annual FEV 1 decline was highest (36731 ml/year) for the upper tertile (increase in CRP concentration over time), lowest (24731 ml/ year) for the lower tertile (decrease in CRP concentration over time), and intermediate (30731 ml/year) in the second tertile (Po0:001). Similar results were obtained after adjustment for baseline factors (P ¼ 0:002): the greater the increase in CRP concentration, the steeper the decline of FEV 1 . Subjects in the upper tertile for changes in CRP concentration displayed a greater annual FEV 1 decline than subjects in the lower tertile (13 ml greater for men and 11 ml greater for women), whereas the annual decline in FEV 1 is around 30 ml/year in adults. 23 Adding changes over time in confounding factors (smoking habits, asthma, atopy, BMI, and lipid concentrations) to the multivariate model did not alter these findings (Table 5) . Similar results were obtained if analyzes were carried out after excluding asthmatics, separately in men and in women, and according to baseline smoking habits (Table 5) .
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Discussion
In this population-based study, conducted in young and middle-aged subjects, FEV 1 and serum CRP concentration were negatively related both in cross-sectional and in longitudinal analyzes. These associations were independent of potential confounding factors (particularly smoking habits) and were observed in subgroups defined on the basis of sex, smoking habits and asthma status. This is the first longitudinal study to investigate the relationship between serum CRP concentration and lung function decline. Cross-sectional relationships between inflammation and lung function has been demonstrated previously in even larger population samples. 18, 20 Some studies have shown that severe (FEV 1 o 50% of predicted) and moderate (FEV 1 50-80% of predicted) COPD is associated with lowgrade systemic inflammation. 24, 25 Our study confirms and extends previous findings by demonstrating the presence of systemic inflammation even in subjects with modest decreases in pulmonary function. These associations seem to be relatively strong and may be considered clinically relevant. Subjects in the upper tertile for change in CRP concentration had an excess annual FEV 1 decline of 13 ml for men and 11 ml for women over subjects in the lower tertile.
Baseline CRP levels also tended to be related to annual FEV 1 decline. However, the association was of borderline statistical significance. This may reflect the low levels of variability in CRP responses in healthy young and middle-aged subjects. Moreover, analyzes based on a single baseline measurement and the within-person variability of CRP will tend to underestimate the effect of CRP on subsequent pulmonary function decline (regression dilution bias). 26 The strengths of this study include the use of data from a general population sample with highquality, standardized measurements, as part of the ECRHS. 27, 28 We were able to confirm previously reported associations between annual FEV 1 decline and major risk factors, including baseline age, smoking habits and BMI, and the associations of CRP with BMI and with smoking habits observed are consistent with previously published results. [28] [29] [30] Although the rate of participation in this study (around 60%) is acceptable for such a long follow-up study in the general population (mean of 8.5 years), we cannot rule out the possibility that there was a selection bias. Nevertheless, our population consisted mostly of young and middle-aged adults, so a significant proportion of the subjects lost to follow-up probably simply moved out of the area. Furthermore, our comparisons of participating and excluded subjects identified no differences in pulmonary parameters and CRP concentrations between these two groups.
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We also analyzed the extent to which these associations were accounted for by confounding factors, such as smoking. It is now widely accepted that smoking is the main risk factor for reduced pulmonary function and COPD. 31 Compounds present in tobacco smoke also penetrate into the bloodstream, and are associated with a higher prevalence of coronary artery disease, endothelial dysfunction, and high serum concentrations of markers of systemic inflammation. [32] [33] [34] High CRP concentrations may reflect the effects of smoking, but adjustment for smoking habits had no effect on the observed association, and the observation that changes in CRP concentration were associated with FEV 1 decline in those who had never smoked renders it unlikely that this association is due to smoking.
Unknown or, to a lesser extent, unmeasured underlying conditions generating both high serum CRP concentrations and impaired pulmonary function via other mechanisms, may also result in confounding effects. The exclusion of subjects with CRP concentrations 410 mg/l (n ¼ 9) had little or no effect on the reported associations.
The reasons for the inverse association between systemic inflammation and reduced pulmonary function are unclear but several mechanisms may be involved. Firstly, reduced lung function may be responsible for the observed systemic inflammation. Like hepatocytes, inflammatory lung or pulmonary epithelial cells, have been shown to express CRP and IL-6. 35, 36 COPD, a leading cause of reduced FEV 1 , is characterized by major lung inflammation. 37 This condition is associated with high serum concentrations of CRP and IL-6. 24, 38 The production of IL-6 in the airways also increases in COPD. 41 IL-6 may reach the bloodstream, stimulating the production of CRP and other inflammatory mediators by the liver, sequentially activating pulmonary inflammatory cells during transit through the pulmonary circulation. 39 It was recently shown that inhaled corticosteroids may down-regulate IL-6 production in the airways, leading to a decrease in liver CRP production in patients with COPD. 40 An alternative mechanismreverse causation-cannot be excluded. High levels of cytokines and acute-phase reactants in the peripheral circulation may be a cause rather than a consequence of poor lung function. There is increasing evidence that cytokines-especially IL-6, which is the chief stimulator of CRP production-play a major role linked to the activation and adhesion of inflammatory cells to the pulmonary capillary endothelium, leading to changes in endothelial function and increases in pulmonary vascular filtration. [41] [42] [43] The persistence of systemic inflammation, and pulmonary micro-filtration, may result in damage to the airways, accelerating the age-related decline in FEV 1 and leading to COPD.
Conclusion
The results of this population-based study suggest, for the first time, that increases in serum CRP concentration over time are associated with a significant decline of pulmonary function, consistent with the hypothesis that low-grade systemic inflammation is associated with pulmonary impairment. However, the nature of these relationships is unclear and merits additional investigation. Further investigations are also needed to determine whether lowering serum CRP concentration could in itself slow FEV 1 decline.
